NZS Capital Added Axogen (AXGN) as an Optionality Position
NZS Capital, LLC, an investment management company, released its “NZS Growth Equity Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Axogen Inc. (AXGN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Aubrey Capital Management Andrew Dalrymple And Barry Mccorkell | 98,700 | $4,559,739 | +14% | 2.86% |
| 2. | RiverPark Advisors Mitch Rubin | 6,216 | $287,117 | +10% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.50 | 2,525 | $26,512.50 | 25,082 | 2024-08-08 | Filing | |
| $6.22 | 10,000 | $62,240.00 | 80,342 | 2023-09-06 | Filing | |
| $6.56 | 10,000 | $65,600.00 | 10,000 | 2023-08-23 | Filing | |
| $6.11 | 10,000 | $61,100.00 | 68,259 | 2023-08-16 | Filing | |
| $14.10 | 14,170 | $199,797.00 | 15,535 | 2019-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $42.60 | 1,647 | $70,162.20 | 93,826 | 2026-05-08 | Filing | |
| $43.26 | 11,050 | $477,967.75 | 0 | 2026-05-07 | Filing | |
| $44.09 | 16,344 | $720,623.30 | 0 | 2026-05-07 | Filing | |
| $43.44 | 4,000 | $173,761.20 | 72,451 | 2026-05-07 | Filing | |
| $43.67 | 573 | $25,022.91 | 65,146 | 2026-05-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,396,792 | $64,517,822 | 0.57% | |
| 2. | 1,295,949 | $59,859,884 | 0.39% | |
| 3. | 1,043,650 | $48,206,194 | 0.06% | |
| 4. | 464,863 | $21,472,022 | 1.69% | |
| 5. | 258,905 | $11,958,822 | 0.13% |
News See All
What Makes Axogen (AXGN) an Investment Bet?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter 2025 investor letter.
AxoGen, Inc. (NASDAQ:AXGN) Q4 2025 Earnings Call Transcript
Operator: Good morning, everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Lindsey Hartley, Chief Financial Officer.
Axogen (AXGN) Benefited from Multiple Tailwinds
Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S.
AxoGen, Inc. (NASDAQ:AXGN) Q3 2025 Earnings Call Transcript
Operator: Good morning. Joining me on today's call is Michael Dale, AxoGen's Chief Executive Officer and Director; and Lindsey Hartley, Chief Financial Officer.
Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Raymond James Slashes PT on Axogen (AXGN) to $20 From $21
Axogen, Inc. (NASDAQ:AXGN) is one of the best medical device stocks to buy according to analysts. On August 6, Raymond James analyst Jayson Bedford lowered the firm’s price target on Axogen, Inc.
12 Best Medical Device Stocks to Buy According to Analysts
On July 7, CNBC’s Chery Kang and Elaine Yu talked about China’s imposition of reciprocal tariffs on the import of medical devices from the European Union.
AxoGen, Inc. (NASDAQ:AXGN) Q2 2025 Earnings Call Transcript
Operator: [Audio Gap] Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Lindsey Hartley, Chief Financial Officer.
Axogen Showcases Nerve Repair Vision at Goldman Sachs
Axogen, Inc. (NASDAQ:AXGN) is among the best growth stocks to invest in for the next 5 years. On June 11, 2025, Axogen, Inc.
Hedge Fund Resource Center